T. Ramahi, R. Rohlfs, N. Sheynberg, K. M. Engle, M. Longo
{"title":"-受体阻滞剂在慢性心力衰竭中的临床应用。","authors":"T. Ramahi, R. Rohlfs, N. Sheynberg, K. M. Engle, M. Longo","doi":"10.1111/J.1527-5299.2001.00253.X","DOIUrl":null,"url":null,"abstract":"Beta blockers improve survival and reduce morbidity of patients with chronic heart failure. Stringent dosing guidelines calling for a 1-hour observation period after initiation or up-titration of beta-blocker therapy might limit the use of beta blockers and increase the expense involved. This study was conducted to determine the usefulness of this observation period. Data were collected from 130 in-clinic postdosing observation periods for 34 stable chronic heart failure patients started on carvedilol. The mean left ventricular ejection fraction was 0.22±0.09, and the mean functional class was 2.5±0.6. No patient had greater than first-degree heart block. Carvedilol was started at 3.125 or 6.25 mg b.i.d., and the dose was doubled every 1-3 weeks. All patients were observed for 1-2 hours after initiation or dosage increase, and blood pressure and heart rate were measured hourly. The maximal daily dose was 50±31 mg. In none of the observation periods was there a decrease in the dose of beta blockers administered in the clinic. The predosing mean blood pressure was 110±15/71±10 mm Hg, and the mean heart rate was 78±13 bpm; the 1-hour postdosing mean blood pressure was 101±14/67±10 mm Hg (p is less than 0.001), and the heart rate was 78±13 bpm. The dose was decreased in six patients and medication was discontinued in three, all consequent to symptoms reported several days after dosage increase. Beta blockers can be safely initiated and up-titrated at home in properly selected and evaluated stable patients with chronic heart failure and severe left ventricular dysfunction resulting in mild or moderate impairment of functional capacity. (c)2001 by CHF, Inc.","PeriodicalId":10536,"journal":{"name":"Congestive heart failure","volume":"78 1","pages":"196-200"},"PeriodicalIF":0.0000,"publicationDate":"2001-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinic dosing of beta blockers in chronic heart failure.\",\"authors\":\"T. Ramahi, R. Rohlfs, N. Sheynberg, K. M. Engle, M. Longo\",\"doi\":\"10.1111/J.1527-5299.2001.00253.X\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Beta blockers improve survival and reduce morbidity of patients with chronic heart failure. Stringent dosing guidelines calling for a 1-hour observation period after initiation or up-titration of beta-blocker therapy might limit the use of beta blockers and increase the expense involved. This study was conducted to determine the usefulness of this observation period. Data were collected from 130 in-clinic postdosing observation periods for 34 stable chronic heart failure patients started on carvedilol. The mean left ventricular ejection fraction was 0.22±0.09, and the mean functional class was 2.5±0.6. No patient had greater than first-degree heart block. Carvedilol was started at 3.125 or 6.25 mg b.i.d., and the dose was doubled every 1-3 weeks. All patients were observed for 1-2 hours after initiation or dosage increase, and blood pressure and heart rate were measured hourly. The maximal daily dose was 50±31 mg. In none of the observation periods was there a decrease in the dose of beta blockers administered in the clinic. The predosing mean blood pressure was 110±15/71±10 mm Hg, and the mean heart rate was 78±13 bpm; the 1-hour postdosing mean blood pressure was 101±14/67±10 mm Hg (p is less than 0.001), and the heart rate was 78±13 bpm. The dose was decreased in six patients and medication was discontinued in three, all consequent to symptoms reported several days after dosage increase. Beta blockers can be safely initiated and up-titrated at home in properly selected and evaluated stable patients with chronic heart failure and severe left ventricular dysfunction resulting in mild or moderate impairment of functional capacity. (c)2001 by CHF, Inc.\",\"PeriodicalId\":10536,\"journal\":{\"name\":\"Congestive heart failure\",\"volume\":\"78 1\",\"pages\":\"196-200\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2001-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Congestive heart failure\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/J.1527-5299.2001.00253.X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Congestive heart failure","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/J.1527-5299.2001.00253.X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
-受体阻滞剂提高慢性心力衰竭患者的生存率并降低发病率。严格的剂量指南要求在β受体阻滞剂治疗开始或增加剂量后1小时的观察期,这可能会限制β受体阻滞剂的使用,并增加相关费用。进行这项研究是为了确定这一观察期的有用性。收集了34例开始服用卡维地洛的稳定型慢性心力衰竭患者的130个临床给药后观察期的数据。左室射血分数平均值为0.22±0.09,功能评分平均值为2.5±0.6。没有患者有超过一级的心脏传导阻滞。卡维地洛起始剂量为3.125或6.25 mg b.i.d,每1-3周加倍剂量。所有患者在起始或增加剂量后观察1-2小时,每小时测量血压和心率。最大日剂量为50±31 mg。在所有的观察期内,临床使用的受体阻滞剂的剂量都没有减少。给药前平均血压为110±15/71±10 mm Hg,平均心率为78±13 bpm;给药后1小时平均血压为101±14/67±10 mm Hg (p < 0.001),心率为78±13 bpm。6名患者减少剂量,3名患者停药,所有这些都是由于在剂量增加后几天报告的症状。慢性心力衰竭和严重左心室功能障碍导致轻度或中度功能障碍的稳定患者可以在家中安全地开始使用-受体阻滞剂并提高剂量。(c)2001年,CHF, Inc。
Clinic dosing of beta blockers in chronic heart failure.
Beta blockers improve survival and reduce morbidity of patients with chronic heart failure. Stringent dosing guidelines calling for a 1-hour observation period after initiation or up-titration of beta-blocker therapy might limit the use of beta blockers and increase the expense involved. This study was conducted to determine the usefulness of this observation period. Data were collected from 130 in-clinic postdosing observation periods for 34 stable chronic heart failure patients started on carvedilol. The mean left ventricular ejection fraction was 0.22±0.09, and the mean functional class was 2.5±0.6. No patient had greater than first-degree heart block. Carvedilol was started at 3.125 or 6.25 mg b.i.d., and the dose was doubled every 1-3 weeks. All patients were observed for 1-2 hours after initiation or dosage increase, and blood pressure and heart rate were measured hourly. The maximal daily dose was 50±31 mg. In none of the observation periods was there a decrease in the dose of beta blockers administered in the clinic. The predosing mean blood pressure was 110±15/71±10 mm Hg, and the mean heart rate was 78±13 bpm; the 1-hour postdosing mean blood pressure was 101±14/67±10 mm Hg (p is less than 0.001), and the heart rate was 78±13 bpm. The dose was decreased in six patients and medication was discontinued in three, all consequent to symptoms reported several days after dosage increase. Beta blockers can be safely initiated and up-titrated at home in properly selected and evaluated stable patients with chronic heart failure and severe left ventricular dysfunction resulting in mild or moderate impairment of functional capacity. (c)2001 by CHF, Inc.